SCHEMBL2293941

SCHEMBL2293941

O=C(Nc1ccc(F)cc1C(=O)O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.73
KCNK2 O95069 1/20 0.60
IGF2BP2 Q9Y6M1 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 2/20 0.55
NR1H4 Q96RI1 2/20 0.55
HPSE Q9Y251 1/20 0.54
HDAC1 Q13547 1/20 0.53
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.53
RAB9A P51151 1/20 0.53
MEN1 O00255 1/20 0.52
PKM P14618 1/20 0.52
GRIK1 P39086 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292513 0.90 SERPINE1 (0.62) SERPINE1SMN1; SMN2LMNAL3MBTL1MAPT
SCHEMBL2295612 0.86 CYP1A2 (0.64) SERPINE1KCNK2SMN1; SMN2LMNANPC1
SCHEMBL2291684 0.86 SERPINE1 (0.61) SERPINE1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL2273634 0.86 SERPINE1 (0.60) SERPINE1KCNK2SMN1; SMN2LMNAL3MBTL1
SCHEMBL2293270 0.85 SERPINE1 (0.70) SERPINE1KCNK2IGF2BP2MAPTNR1H4
SCHEMBL418988 0.84 SERPINE1 (1.00) SERPINE1KCNK2SMN1; SMN2LMNAL3MBTL1
SCHEMBL29838671 0.84 SERPINE1 (1.00) SERPINE1KCNK2SMN1; SMN2LMNAL3MBTL1
SCHEMBL2292518 0.83 SERPINE1 (0.71) SERPINE1KCNK2SMN1; SMN2NPC1RAB9A
SCHEMBL20513012 0.82 MAPT (0.79) SERPINE1KCNK2IGF2BP2LMNAMAPT
SCHEMBL2291520 0.82 SMN1; SMN2 (0.57) SERPINE1SMN1; SMN2LMNAL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 SERPINE1 3616/4885KCNK2 3279/4885IGF2BP2 4867/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 SERPINE1 3954/4885KCNK2 2982/4885IGF2BP2 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.